Interview with Garry Neil on TransCelerate BioPharmaSeptember 20, 2012 | BioPharm America™ 2012Garry Neil explains the impetus behind and goals of TransCelerate BioPharma, a new nonprofit organization focused on accelerating the development of new medicines.View session here Interview with David de Graaf of SelventaSeptember 20, 2012 | BioPharm America™ 2012David de Graaf of Selventa is pioneering the development of a new class of innovative "Systems Diagnostics" for personalized medicine.View session here Interview with John Brooks, Joslin Diabetes CenterSeptember 20, 2012 | BioPharm America™ 2012John Brooks is positioning the Joslin Diabetes Center as the hub of innovation and research partnerships in diabetes. View session here Interview Jason Rhodes of EpizymeSeptember 20, 2012 | BioPharm America™ 2012Epizyme is aiming to create personalized therapeutics for patients with genetically-defined cancers using a branch of epigenetics called histone methyltransferases (HMTs)View session here Interview with Kevin Krenitsky of Foundation MedicineSeptember 20, 2012 | BioPharm America™ 2012Foundation Medicine is blazing new trails in personalized medicine for cancer patients.View session here From start-up to commercial company and the challenges in between: Could we do it again today?September 20, 2012 | BioPharm America™ 2012Karen Bernstein of BioCentury leads a discussion of the challenges in taking a company from start-up to commercial success. How is this different today than in years past?View session here Is there a downward trend in diabetes treatment innovation? And if so, what can we do about it?September 20, 2012 | BioPharm America™ 2012Diabetes continues, despite major treatment advances, to warrant new, novel therapies to further help patients gain better control of their disease. How are we doing? View session here Best deal structures: How do you operationalize external R&D? September 19, 2012 | BioPharm America™ 2012There is no universally accepted model for externalizing R&D successfully and many key considerations to be weighed in how to create and operationalize these programs.View session here Emerging markets: Redefining global drug development strategySeptember 19, 2012 | BioPharm America™ 2012Life science firms are rethinking the paradigms of global drug development due to growing market potential outside Western markets in emerging patient populations.View session here Fierce 15 revealedSeptember 19, 2012 | BioPharm America™ 2012John Carroll, Editor of FierceBiotech, discusses the current landscape in life sciences with Fierce 15 CEOs. The 2012 Fierce 15 selection was revealed the week of the conference.View session here New financing models for creative exit strategiesSeptember 19, 2012 | BioPharm America™ 2012Whether constructing new types of licensing deals or rethinking the corporate structure, companies hope to once again make private biotech companies attractive investments. View session here An exploration of new roles along the drug development value chain: Who’s in, who’s out, and are the new occupants positioned to succeed?September 19, 2012 | BioPharm America™ 2012New roles are being assumed along the drug development value chain. Who has vacated these roles? Are the new occupants positioned to succeed?View session here
© 20092013 EBD Group, Inc.